{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:58:33Z","timestamp":1790470713371,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004886","name":"Cancer Research Foundation in Northern Sweden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.tranon.2019.09.007","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T18:12:36Z","timestamp":1575310356000},"page":"86-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case\u2013Control Study in Northern Sweden"],"prefix":"10.1016","volume":"13","author":[{"given":"Sarah","family":"Jonsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Elgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Ottander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Idahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tranon.2019.09.007_bib1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch : Int J Pathol"},{"issue":"Suppl 10","key":"10.1016\/j.tranon.2019.09.007_bib2","doi-asserted-by":"crossref","first-page":"x16","DOI":"10.1093\/annonc\/mdt463","article-title":"Origin and molecular pathogenesis of ovarian high-grade serous carcinoma","volume":"24","author":"Kurman","year":"2013","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"issue":"11","key":"10.1016\/j.tranon.2019.09.007_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110433","article-title":"Cell origins of high-grade serous ovarian cancer","volume":"10","author":"Kim","year":"2018","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.tranon.2019.09.007_bib4","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1200\/JCO.2016.66.8178","article-title":"Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium","volume":"34","author":"Wentzensen","year":"2016","journal-title":"J\u00a0Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.tranon.2019.09.007_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.15698\/mic2016.09.525","article-title":"Chlamydia trachomatis genital infections","volume":"3","author":"O'Connell","year":"2016","journal-title":"Microb Cell"},{"issue":"2","key":"10.1016\/j.tranon.2019.09.007_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.contraception.2015.01.004","article-title":"Pathogenesis of fallopian tube damage caused by Chlamydia trachomatis infections","volume":"92","author":"Hafner","year":"2015","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.tranon.2019.09.007_bib7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0015-0282(16)47489-3","article-title":"Host response to primary Chlamydia trachomatis infection of the fallopian tube in pig-tailed monkeys","volume":"40","author":"Patton","year":"1983","journal-title":"Fertil Steril"},{"issue":"6","key":"10.1016\/j.tranon.2019.09.007_bib8","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/infdis\/159.6.1105","article-title":"Experimental Chlamydia trachomatis salpingitis in mice: initial studies on the characterization of the leukocyte response to chlamydial infection","volume":"159","author":"Patton","year":"1989","journal-title":"J\u00a0Infect Dis"},{"issue":"6","key":"10.1016\/j.tranon.2019.09.007_bib9","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.chom.2013.05.010","article-title":"Chlamydia infection promotes host DNA damage and proliferation but impairs the DNA damage response","volume":"13","author":"Chumduri","year":"2013","journal-title":"Cell Host Microbe"},{"issue":"4","key":"10.1016\/j.tranon.2019.09.007_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1084\/jem.187.4.487","article-title":"Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation","volume":"187","author":"Fan","year":"1998","journal-title":"J\u00a0Exp Med"},{"issue":"9","key":"10.1016\/j.tranon.2019.09.007_bib11","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1073\/pnas.90.9.3998","article-title":"Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro","volume":"90","author":"Beatty","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.tranon.2019.09.007_bib12","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1128\/IAI.69.4.2442-2447.2001","article-title":"Persistent Chlamydia trachomatis infections resist apoptotic stimuli","volume":"69","author":"Dean","year":"2001","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.tranon.2019.09.007_bib13","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1128\/iai.62.9.3705-3711.1994","article-title":"Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence","volume":"62","author":"Beatty","year":"1994","journal-title":"Infect Immun"},{"issue":"7225","key":"10.1016\/j.tranon.2019.09.007_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/457036b","article-title":"Cancer: inflaming metastasis","volume":"457","author":"Mantovani","year":"2009","journal-title":"Nature"},{"issue":"6917","key":"10.1016\/j.tranon.2019.09.007_bib15","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.tranon.2019.09.007_bib16","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1086\/368380","article-title":"Serologic evidence of past infection with Chlamydia trachomatis, in relation to ovarian cancer","volume":"187","author":"Ness","year":"2003","journal-title":"J\u00a0Infect Dis"},{"issue":"9","key":"10.1016\/j.tranon.2019.09.007_bib17","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10096-012-1570-5","article-title":"Viral and bacterial aetiologies of epithelial ovarian cancer","volume":"31","author":"Shanmughapriya","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis : Off Publ Eur Soc Clin Microbiol"},{"key":"10.1016\/j.tranon.2019.09.007_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/IJWH.S188938","article-title":"Chlamydia trachomatis infection in primary fallopian tube and high-grade serous ovarian cancers: a pilot study","volume":"11","author":"Laban","year":"2019","journal-title":"Int J Womens Health"},{"issue":"5","key":"10.1016\/j.tranon.2019.09.007_bib19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1086\/516454","article-title":"Antibody to chlamydial hsp60 predicts an increased risk for chlamydial pelvic inflammatory disease","volume":"175","author":"Peeling","year":"1997","journal-title":"J\u00a0Infect Dis"},{"issue":"2","key":"10.1016\/j.tranon.2019.09.007_bib20","first-page":"249","article-title":"Chlamydia trachomatis detection in a population of asymptomatic and symptomatic women: correlation with the presence of serological markers for this infection","volume":"31","author":"Mascellino","year":"2008","journal-title":"New Microbiol"},{"key":"10.1016\/j.tranon.2019.09.007_bib21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.canep.2018.05.011","article-title":"Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer","volume":"55","author":"Stewart","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"10.1016\/j.tranon.2019.09.007_bib22","first-page":"415","article-title":"Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis","volume":"28","author":"Zhou","year":"2017","journal-title":"Cancer Causes Control : CCC (Cancer Causes Control)"},{"issue":"1","key":"10.1016\/j.tranon.2019.09.007_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrc1251","article-title":"Mucins in cancer: protection and control of the cell surface","volume":"4","author":"Hollingsworth","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2019.09.007_bib24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2559.2010.03667.x","article-title":"Expression of aberrantly glycosylated Mucin-1 in ovarian cancer","volume":"57","author":"Van Elssen","year":"2010","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.tranon.2019.09.007_bib25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s002620050484","article-title":"Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women","volume":"46","author":"Richards","year":"1998","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.tranon.2019.09.007_bib26","first-page":"1125","article-title":"Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research","volume":"14","author":"Cramer","year":"2005","journal-title":"Am Soc Prev Oncol"},{"issue":"1","key":"10.1016\/j.tranon.2019.09.007_bib27","first-page":"30","article-title":"Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research","volume":"16","author":"Terry","year":"2007","journal-title":"Am Soc Prev Oncol"},{"issue":"6","key":"10.1016\/j.tranon.2019.09.007_bib28","first-page":"1595","article-title":"Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research","volume":"19","author":"Pinheiro","year":"2010","journal-title":"Am Soc Prev Oncol"},{"key":"10.1016\/j.tranon.2019.09.007_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/14034950310001432","article-title":"Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort - evaluation of risk factors and their interactions","volume":"61","author":"Hallmans","year":"2003","journal-title":"Scand J Public Health Suppl"},{"key":"10.1016\/j.tranon.2019.09.007_bib30","doi-asserted-by":"crossref","DOI":"10.3402\/gha.v3i0.4643","article-title":"The Vasterbotten Intervention Programme: background, design and implications","volume":"3","author":"Norberg","year":"2010","journal-title":"Glob Health Action"},{"issue":"5","key":"10.1016\/j.tranon.2019.09.007_bib31","first-page":"719","article-title":"Maternal hormones during early pregnancy: a cross-sectional study","volume":"21","author":"Chen","year":"2010","journal-title":"Cancer Causes Control : CCC (Cancer Causes Control)"},{"issue":"1","key":"10.1016\/j.tranon.2019.09.007_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","article-title":"Histopathologic grading of ovarian carcinoma: a review and proposal","volume":"19","author":"Silverberg","year":"2000","journal-title":"Int J Gynecol Pathol : Off J Int Soc Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.tranon.2019.09.007_bib33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","article-title":"MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study","volume":"6","author":"Kimura","year":"2013","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.tranon.2019.09.007_bib34","doi-asserted-by":"crossref","first-page":"219672","DOI":"10.1155\/2008\/219672","article-title":"Chlamydia trachomatis serology in women with and without ovarian cancer","volume":"2008","author":"Ness","year":"2008","journal-title":"Infect Dis Obstet Gynecol"},{"key":"10.1016\/j.tranon.2019.09.007_bib35","doi-asserted-by":"crossref","first-page":"824627","DOI":"10.1155\/2011\/824627","article-title":"Chlamydia trachomatis and Mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors","volume":"2011","author":"Idahl","year":"2011","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.tranon.2019.09.007_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnci\/djy084","article-title":"Antibodies against Chlamydia trachomatis and ovarian cancer risk in two independent populations","volume":"111","author":"Trabert","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.tranon.2019.09.007_bib37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/s41416-019-0422-9","article-title":"Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies","volume":"120","author":"Fortner","year":"2019","journal-title":"Br J Canc"},{"issue":"7","key":"10.1016\/j.tranon.2019.09.007_bib38","first-page":"790","article-title":"Anti-CA15.3 and anti-CA125 antibodies and ovarian cancer risk: results from the EPIC cohort. Cancer epidemiology, biomarkers & prevention : a publication of the American association for cancer research","volume":"27","author":"Cramer","year":"2018","journal-title":"Am Soc Prev Oncol"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523319302992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523319302992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:37:14Z","timestamp":1761835034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523319302992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1936523319302992"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2019.09.007","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case\u2013Control Study in Northern Sweden","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2019.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}]}}